Alnylam Pharmaceuticals (NASDAQ: ANLY)Portfolio:Approval of OXLUMO™ (lumasiran) and Expected approval of LEQVIO® (inclisiran) By End of 2020

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system/ocular diseases. 

The commercially approved products include

• ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and 
• GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP). 

Platform
RNAi therapies leverage two distinct approaches to enable the delivery of small interfering Ribonucleic Acid (siRNA): lipid nanoparticles (LNP) and GalNAc-conjugates

Stock Symbol: ANLY

Therapeutic Area (Late Stage)

• Hereditary ATTR amyloidosis,
• Hemophilia,
• Hypercholesterolemia, and
• Primary hyperoxaluria type 1

Q3 2020 Highlights 

• ONPATTRO® Global Net Product Revenue of $82.5 Million, 
• GIVLAARI® Global Net Product Revenue of $16.7 Million
• Received Positive Opinions for OXLUMO™ (lumasiran) and LEQVIO® (inclisiran) from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)

For detail, visit https://www.alnylam.com